Skip to content

Analysis of the Effect of Aromatherapy on Preventing Nausea and Vomiting in Cancer Patients During Chemotherapy: A Randomized Controlled Study

Analysis of the Effect of Aromatherapy on Preventing Nausea and Vomiting in Cancer Patients During Chemotherapy: A Randomized Controlled Study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600129554
Enrollment
Unknown
Registered
2026-08-06
Start date
2025-04-16
Completion date
Unknown
Last updated
2026-08-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer

Interventions

Intervention group:Based on the standard anti-nausea protocol, 5 minutes before each chemotherapy session, the researchers applied three drops of essential oil onto a 5cm×5cm sterile gauze, and fixed
Control group:The control group was given the standard antiemetic regimen, along with routine oncology care, which included health education on medication, diet, and exercise.

Sponsors

Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 84 Years

Inclusion criteria

Inclusion criteria: 1. Age >= 18 years; 2. Diagnosed with malignant tumor, with no restrictions on tumor type, and receiving chemotherapy based on platinum compounds; 3. Expected survival period greater than 3 months; 4. ECOG score 0-2; 5. No other diseases causing nausea and vomiting, such as increased intracranial pressure, brain metastasis, intestinal obstruction or liver and kidney diseases, etc.; 6. No abnormal sense of smell or respiratory system diseases such as asthma or rhinitis in the patient; 7. Signed a written informed consent form and voluntarily agreed to participate in this study.

Exclusion criteria

Exclusion criteria: 1. Allergic to the ingredients in this product; 2. Used other antiemetic drugs 24 hours before chemotherapy; 3. Having coagulation dysfunction; 4. Having severe cardiovascular diseases, liver and kidney dysfunction, respiratory system diseases or other infectious diseases; 5. Undergoing radiotherapy simultaneously; 6. Having received similar intervention measures within one month prior to the start of this study; 7. Impairments in activities, language, hearing, cognitive functions or mental disorders.

Design outcomes

Primary

MeasureTime frame
( Chemotherapy-Induced Nausea and Vomiting,CINV;

Secondary

MeasureTime frame
Functional Living Index-Emesis;

Countries

China

Contacts

Public ContactXie xinxin

Sun Yat-sen Memorial Hospital, Sun Yat-sen University

xiexinxin2020@126.com+86 136 8220 1164

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Aug 25, 2026